Reagent DC viabilitya Early apoptosisb Late apoptosisc
NI 1.59 × 106 ± 142 35 ± 0.01 10 ± 0.05
LLO91-99 (μg/ml)
500
50
5
0.5		 1.49 × 106 ± 132
1.59× 106 ± 120
1.58 × 106 ± 113
1.59 × 106 ± 128		 36 ± 0.02
37 ± 0.03
35 ± 0.02
36 ± 0.01		 11 ± 0.02
12 ± 0.08
10 ± 0.09
11 ± 0.03
LLO189-201 (μg/ml)
500
50
5
0.5		 1.59 × 106 ± 132
1.57× 106 ± 120
1.58 × 106 ± 113
1.59 × 106 ± 128		 36 ± 0.02
37 ± 0.03
35 ± 0.02
36 ± 0.01		 10 ± 0.03
12 ± 0.07
12 ± 0.08
11 ± 0.01
LLO190-201 (μg/ml)
500
50
5
0.5		 1.59 × 106 ± 132
1.56× 106 ± 120
1.58 × 106 ± 113
1.59 × 106 ± 128		 36 ± 0.02
35 ± 0.03
37 ± 0.02
36 ± 0.01		 11 ± 0.01
10 ± 0.05
12 ± 0.05
11 ± 0.07
LLO190-201 (μg/ml)
500
50
5
0.5		 1.59 x 106 ± 132
1.58 x 106 ± 120
1.58 x 106 ± 113
1.59 x 106 ± 128		 36 ± 0.02
37 ± 0.03
35 ± 0.02
36 ± 0.01		 11 ± 0.10
12 ± 0.15
10 ± 0.05
11 ± 0.07
LLO296-304 (μg/ml)
500
50
5
0.5		 1.59 × 106 ± 132
1.57× 106 ± 120
1.58 × 106 ± 113
1.59 ×106 ± 128		 36± 0.02
37 ± 0.03
35 ± 0.02
36 ± 0.01		   10 ± 0.10
12 ± 0.15
11 ± 0.05
11 ± 0.07
GAPDH1-15 (μg/ml)
500
50
5
0.5		 1.59 × 106 ± 132
1.58× 106 ± 120
1.58 × 106 ± 113
1.59 × 106 ± 128		 35 ± 0.02
36 ± 0.03
35 ± 0.02
36 ± 0.01		 10 ± 0.01
11 ± 0.05
10 ± 0.02
12 ± 0.03
GAPDH1-22 (μg/ml)
500
50
5
0.5		 1.59 × 106 ± 132
1.58× 106 ± 120
1.58 × 106 ± 113
1.59 × 106± 128		 36 ± 0.02
37 ± 0.03
37 ± 0.02
36 ± 0.01		 11 ± 0.02
12 ± 0.01
12 ± 0.03
11 ± 0.01
Table 1: Lack of toxicity of different LLO and GAPDH peptides. aIn vitro toxicity assayed into DC incubated with peptides for 24 hours and next stained with Trypan blue. Results are expressed as the number of cells ± SD and experiments were performed in triplicates (P<0.05). bDC were incubated with peptides for 24 hours and next incubated with 7-ADD and annexin V to analyse fluorescence by FACS. Results are expressed as the percentages of late apoptotic cells or necrotic death, (Q2 in Figure S1) (P<0.05). cPercentages of early apoptotic cells or programmed cell death (Q4 in Figure S1) (mean ± SD) (p<0.05).